Navigation Links
Unilateral radiation therapy for advanced stage tonsil cancer results in favorable outcomes
Date:2/20/2014

Scottsdale, Ariz., February 20, 2014Limiting radiation therapy to lymph nodes on one side of the neck for advanced tonsil cancer resulted in good local regional control and no cancer recurrence on the untreated side, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium. Additionally, the study results indicate that primary tumor location, rather than the amount of lymph node involvement on the tumor side of the neck, dictates the risk for disease in the opposite side of the neck.

The study focused on 46 out of 153 total patients with squamous cell carcinoma of the tonsil who received treatment between 1997 and 2012 at Washington University in St. Louis. Tumor location was well-documented in the 46 patients who received unilateral radiation therapy (RT), with 40 patients (87 percent) having lateralized (located on one side of the throat) primary tumors; two patients (4 percent) had non-lateralized tumors, and in four patients (9 percent), lateralization could not be determined retrospectively. The patients underwent surgical resection and postoperative intensity modulated radiation therapy (IMRT), with 30 patients also receiving concurrent chemotherapy.

Of the subset of 46 patients treated unilaterally, 72 percent were men, and the average patient age was 59. Sixty-one percent of patients were current or former smokers. The cancer stage/classification for the study group was: TX = 2 percent (1); T1 = 44 percent (20); T2 = 41 percent (19); and T3 = 13 percent (6). The patients' stages of lymph node involvement were: N0 = 11 percent (5); N1 = 13 percent (6); and N2 = 76 percent (35). The prescribed radiation doses were 60-66 Gy to the postoperative bed and involved neck; and 52-54 Gy to the elective neck in 30-33 fractions using a simultaneous integrated boost technique.

The median follow-up period was 2.8 years (range was .4 to 8.7 years). There were no local or regional recurrences reported, meaning the cancer did not recur in the adjacent nodes or the original location of the cancer in any of the patients. Distant metastasis, meaning the cancer spread from the original tumor site to distant organs or lymph nodes, developed in four (9 percent) of the patients. Two patients developed second primary (new) cancers.

"All treatments for cancersurgery, radiation therapy, chemotherapyalthough effective, can cause temporary and/or permanent toxicity which can affect long-term quality of life," said study author Wade Thorstad, MD, chief of Head and Neck Services and associate professor of Radiation Oncology at Washington University School of Medicine. "Our research indicates that for appropriately selected patients with tonsil cancer, the volume of radiation therapy necessary to control the cancer can be significantly reduced, therefore reducing the side effects and toxicity of radiation, while maintaining a high rate of tumor control."


'/>"/>
Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
3. CT Scans Deliver More Radiation to Obese People: Study
4. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
5. Study examines adverse effects among different radiation therapies for prostate cancer
6. Chemo + Radiation Best for Bladder Cancer, Study Finds
7. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
8. APBI associated with more mastectomies, toxicities, complications, compared to traditional radiation
9. Cone beam CT proves better for visualizing some causes of hearing loss at half the radiation dose
10. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
11. Novel biomarkers reveal evidence of radiation exposure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... Ca (PRWEB) , ... August 18, 2017 , ... ... quality liquid handling handheld devices. Through an educational webinar, they will present the ... users a chance to learn how easy you can automate everyday pipetting tasks. ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
(Date:8/18/2017)... ... , ... “Emotions are sacred, valid, honored, encouraged. This is the memo we ... Mindful. To help change the mindset of parents and educators from punitive to positive ... Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in less ...
(Date:8/18/2017)... ... , ... Alcovit, a lime-flavored beverage that rids the body of toxins linked ... now available through Jet.com. , After 25 years of development, the company released ... to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: